Program
lenvatinib
Also written as “Lenvatinib”, “E7080” and “HOPE”.
Its studies are mostly in Carcinoma, Hepatocellular · Melanoma · Thyroid Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 4 companies.
Drug pageLenvatinib: every studyAll 431 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisaiits history only | 511 open or running | phase 4since Jun 19, 2018 | Jul 15, 2005 | none ahead |
| Merckits history only | 261 open or running | phase 3since Jan 22, 2019 | Aug 3, 2016 | Oct 22, 2027phase 2 · NCT02861573 |
| AGO Researchits history only | 11 open or running | phase 2since May 11, 2023 | May 11, 2023 | Oct 30, 2027phase 2 · NCT05903833 |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 1since Oct 4, 2021 | Oct 4, 2021 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical, PharmaBio Development and Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 4, 2021First study: phase 1 study in Central Nervous System NeoplasmsFirst studyNCT05081180 · 17 enrolled · Canada, France, Germany and more
TargetBeta
“A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase ”NCIt, by rule
“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
Studies
The one study Merck KGaA, Darmstadt, Germany leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05081180Central Nervous System Neoplasms · Canada, France, Germany and more | 1 | Terminated | Feb 11, 2026 | 17 |
How it is read
Names in the registry
- “Lenvatinib”, 72 entries
- “lenvatinib”, 7 entries
- “E7080”, 6 entries
- “HOPE”, 2 entries
- “E7080 capsule”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 10 studies
- Melanoma, 7 studies
- Thyroid Neoplasms, 6 studies
- Carcinoma, Non-Small-Cell Lung, 6 studies
- Carcinoma, Renal Cell, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.